Eledon Pharmaceuticals Reports 12th Participant Enrolled In Phase 2 BESTOW Trial Evaluating Tegoprubart For Prevention Of Organ Rejection
Eledon Pharmaceuticals報告稱,第12名參與者參加了評估Tegoprubart預防器官排斥反應的2期試驗
Eledon Pharmaceuticals Reports 12th Participant Enrolled In Phase 2 BESTOW Trial Evaluating Tegoprubart For Prevention Of Organ Rejection
Eledon Pharmaceuticals報告稱,第12名參與者參加了評估Tegoprubart預防器官排斥反應的2期試驗
使用瀏覽器的分享功能,分享給你的好友吧